Literature DB >> 11141143

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk).

K T Khaw1, N Wareham, R Luben, S Bingham, S Oakes, A Welch, N Day.   

Abstract

OBJECTIVE: To examine the value of glycated haemoglobin (HbA(1c)) concentration, a marker of blood glucose concentration, as a predictor of death from cardiovascular and all causes in men.
DESIGN: Prospective population study.
SETTING: Norfolk cohort of European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk).
SUBJECTS: 4662 men aged 45-79 years who had had glycated haemoglobin measured at the baseline survey in 1995-7 who were followed up to December 1999. MAIN OUTCOME MEASURES: Mortality from all causes, cardiovascular disease, ischaemic heart disease, and other causes.
RESULTS: Men with known diabetes had increased mortality from all causes, cardiovascular disease, and ischaemic disease (relative risks 2.2, 3.3, and 4.2, respectively, P <0.001 independent of age and other risk factors) compared with men without known diabetes. The increased risk of death among men with diabetes was largely explained by HbA(1c) concentration. HbA(1c) was continuously related to subsequent all cause, cardiovascular, and ischaemic heart disease mortality through the whole population distribution, with lowest rates in those with HbA(1c) concentrations below 5%. An increase of 1% in HbA(1c) was associated with a 28% (P<0.002) increase in risk of death independent of age, blood pressure, serum cholesterol, body mass index, and cigarette smoking habit; this effect remained (relative risk 1.46, P=0.05 adjusted for age and risk factors) after men with known diabetes, a HbA(1c) concentration >/=7%, or history of myocardial infarction or stroke were excluded. 18% of the population excess mortality risk associated with a HbA(1c) concentration >/=5% occurred in men with diabetes, but 82% occurred in men with concentrations of 5%-6.9% (the majority of the population).
CONCLUSIONS: Glycated haemoglobin concentration seems to explain most of the excess mortality risk of diabetes in men and to be a continuous risk factor through the whole population distribution. Preventive efforts need to consider not just those with established diabetes but whether it is possible to reduce the population distribution of HbA(1c) through behavioural means.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11141143      PMCID: PMC26599          DOI: 10.1136/bmj.322.7277.15

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  47 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

2.  The rising global burden of diabetes and its complications: estimates and projections to the year 2010.

Authors:  A F Amos; D J McCarty; P Zimmet
Journal:  Diabet Med       Date:  1997       Impact factor: 4.359

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population.

Authors:  K Pyörälä; E Savolainen; S Kaukola; J Haapakoski
Journal:  Acta Med Scand Suppl       Date:  1985

5.  Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality.

Authors:  J E Shaw; A M Hodge; M de Courten; P Chitson; P Z Zimmet
Journal:  Diabetologia       Date:  1999-09       Impact factor: 10.122

6.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

7.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

8.  Fasting blood glucose and risk of coronary heart disease, stroke, and all-cause mortality: a 17-year follow-up study of men born in 1913.

Authors:  L O Ohlson; K Svärdsudd; L Welin; H Eriksson; L Wilhelmsen; G Tibblin; B Larsson
Journal:  Diabet Med       Date:  1986-01       Impact factor: 4.359

9.  Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study.

Authors:  J H Fuller; M J Shipley; G Rose; R J Jarrett; H Keen
Journal:  Lancet       Date:  1980-06-28       Impact factor: 79.321

10.  The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.

Authors: 
Journal:  Diabetes       Date:  1995-08       Impact factor: 9.461

View more
  189 in total

1.  "Normal" blood glucose and coronary risk.

Authors:  E Barrett-Connor; D L Wingard
Journal:  BMJ       Date:  2001-01-06

2.  Glycated haemoglobin, diabetes, and mortality in men. Maybe disturbance in physiological mechanisms regulating blood glucose is risk factor for cardiovascular death.

Authors:  R J Jarrett
Journal:  BMJ       Date:  2001-04-21

3.  Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes.

Authors:  April P Carson; Caroline S Fox; Darren K McGuire; Emily B Levitan; Martin Laclaustra; Devin M Mann; Paul Muntner
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-10-05

Review 4.  The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies.

Authors:  Luke W Arnold; Zhiqiang Wang
Journal:  Rev Diabet Stud       Date:  2014-08-10

Review 5.  What should we measure in the diabetic patient and how does this respond to therapy?

Authors:  Desmond G Johnston; Stephen Robinson; Shareen Forbes
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

6.  Hemoglobin A1c as a diagnostic tool: public health implications from an actor-network perspective.

Authors:  Chris Degeling; Melanie Rock
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

7.  Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention.

Authors:  Revathi Balakrishnan; Jeffrey S Berger; Lisa Tully; Anish Vani; Binita Shah; Joseph Burdowski; Edward Fisher; Arthur Schwartzbard; Steven Sedlis; Howard Weintraub; James A Underberg; Ann Danoff; James A Slater; Eugenia Gianos
Journal:  Diabetes Metab Res Rev       Date:  2015-05-12       Impact factor: 4.876

Review 8.  Clinical significance of glycated hemoglobin in the acute phase of ST elevation myocardial infarction.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Maria Grazia D'Alfonso; Gian Franco Gensini
Journal:  World J Cardiol       Date:  2014-04-26

Review 9.  Drugs for cardiovascular risk reduction in the diabetic patient.

Authors:  D S Bell
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

Review 10.  Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes.

Authors:  Milagros G Huerta; Jerry L Nadler
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.